Insights on Insight Gathering
Pharmaceutical Commerce
OCTOBER 28, 2022
Understanding markets, influencers, and patients through better stakeholder engagement and faster analysis.
Sat.Oct 22, 2022 - Fri.Oct 28, 2022
52 
With new startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’
Bio Pharma Dive
OCTOBER 25, 2022
Chen, who discovered the cancer-protecting protein PD-L1, will work closely with startup Normunity to find targets that can help the immune system reach ‘cold’ tumors.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cloud robotics labs are accelerating drug discovery and development
Pharmaceutical Technology
OCTOBER 28, 2022
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Considering the low chances of success, with only 10% of drug candidates making it into clinical development, pharma companies must prevent the increased erosion of profit margins.
Something Toxic Flourishes in Your Brain After Too Much Hard Work
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 24, 2022
A long day in the office can leave you empty of energy and overcome with desire for TV and a takeaway. But you’ve been sitting down all day. So why do you feel as tired as your friends who have physical jobs? Struggling through your list of essential tasks feels ever more grueling as the […].
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
6 Operational Considerations You Need To Know for Psychedelic Trials
Worldwide Clinical Trials
OCTOBER 26, 2022
Bringing a psychedelic into a clinical trial setting is complex and requires a thorough operational approach to ensure the study’s success. Having worked in psychedelic research since the advent of industry-sponsored trials, Worldwide Clinical Trials has amassed the expertise needed to execute these studies successfully, recently sharing insights in a webinar titled “ Demystifying Complex Operations in Psychedelic Research ,” available on-demand now.
Gilead, fueled by latest approval, sees CAR-T sales take off
Bio Pharma Dive
OCTOBER 28, 2022
After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and Johnson & Johnson.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Feeling Stressed Before You Get COVID May Increase Your Odds of Developing Long COVID
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 26, 2022
Millions of people are now suffering from long COVID, which presents with a staggering array of possible symptoms that can linger for months, or even years. To provide more answers to this frustratingly relentless condition, researchers have tested an association between mental stresses and long COVID. These stressors include depression, anxiety, and types of distress […].
Dispensing Pharmacy Packaging Machines: COVID-19 Impact
Pharma Mirror
OCTOBER 22, 2022
Finding a reliable supply of bar-coded, unit-dose pharmaceuticals remains difficult despite measures to improve patient safety. The ability to repackage and bar code drugs to the unit of usage is becoming increasingly necessary in health-system pharmacies. Benefits for pharmacies that invest in a high-throughput unit dose packing machine include improved productivity and management of bar-coded medicine stock.
AstraZeneca extends run of trial successes with breast cancer drug results
Bio Pharma Dive
OCTOBER 26, 2022
On the heels of a major approval for Enhertu, the pharma reported positive results for two experimental drugs in settings where rival medicines from Roche and Sanofi recently failed.
BioMed X and Sanofi partner to leverage AI for drug development
Pharmaceutical Technology
OCTOBER 25, 2022
BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. Under the joint research project, a new research team will be set up at the BioMed X Institute in Heidelberg, Germany. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.
Scientists Grow Fully Functioning Hair Follicles in New Lab First
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 25, 2022
We can add functional mouse hair follicles to body parts that scientists have successfully grown in the lab, outside the body. Using cells obtained from embryonic mice, for the first time researchers were able to produce hair follicle organoids – small, simple versions of an organ – that grew hair. Moreover, they were able to […].
UK lags behind other nations in research and development
Pharma Times
OCTOBER 27, 2022
UK only places 11th in terms of total R&D investment as a percentage of GDP
AstraZeneca’s persistence pays off with Imjudo approval
Bio Pharma Dive
OCTOBER 24, 2022
After failing multiple studies, the company’s immunotherapy tremelimumab is cleared to treat liver cancer as part of a regimen that could challenge a similar drug combination from Bristol Myers Squibb.
US FDA grants approval for AstraZeneca’s combination liver cancer therapy
Pharmaceutical Technology
OCTOBER 25, 2022
The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Imjudo (tremelimumab) plus Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma (HCC), a kind of liver cancer. The dosage and schedule of the combination treatment is named the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab).
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Does Faking a Smile Make You Happier? The Latest Findings Are In
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 27, 2022
Does faking a smile make you feel happier? That question has been debated since famed naturalist Charles Darwin published a book on the subject in 1872. “The free expression by outward signs of an emotion intensifies it… Even the simulation of an emotion tends to arouse it in our minds,” Darwin wrote. Popular culture has […].
Exelixis announces results from trial evaluating XB002
Pharma Times
OCTOBER 27, 2022
Study involves patients with advanced common cancers and solid tumours
An unusual alliance opens a gene and cell therapy hub outside Boston
Bio Pharma Dive
OCTOBER 27, 2022
Landmark Bio, armed with $75 million and a wide range of backers, is the latest company to emerge with plans to open a “bottleneck” slowing development of the complex medicines.
Pharma’s ESG goals need to underscore push for health equity
Pharmaceutical Technology
OCTOBER 26, 2022
Over recent years, many pharmaceutical companies have taken up environment, social and governance (ESG) targets in order to prioritize sustainability whilst boosting their external public relations. On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Indian Ayurveda propels growth with strong industry norms & high herb quality claims: Dr. Rangesh Paramesh
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 27, 2022
Indian Ayurveda propels its growth supported by the industry guidelines of Good Agricultural and Collection Practice (GACP), Good Clinical Practice (GCP), Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP), said Dr. Rangesh Paramesh, director – Intellectual Property, Himalaya Wellness Company. Delving on the topic ‘Key Drivers Determining the Future of the Ayurvedic Drug and […].
Omicron keeps finding new evolutionary tricks to outsmart our immunity
NPR Health - Shots
OCTOBER 25, 2022
SARS-CoV-2 is evolving "rapidly," spawning one new variant after another. But omicron continues to dominate, raising new questions about how evolution of the virus is headed.
GSK, dialing back cell therapy work, ends deals with Lyell and Adaptimmune
Bio Pharma Dive
OCTOBER 25, 2022
The British drugmaker terminated the two alliances following disappointing results this year for a once highly touted cell-based treatment for solid tumors.
AI medtech platform is aiming to tackle drug-resistant pathogens
Pharmaceutical Technology
OCTOBER 27, 2022
Belfast startup AMPLY has raised £900,000 to develop a range of new products that hopes to tackle multi-drug resistent pathogens using its artificial intelligence (AI) drug discovery platform. It hopes to ensure new strains of antibiotics can still tackle global threat diseases, despite antimicrobial resistance. Antimicrobial resistance is when bacteria and viruses become resistant to medication, making previous treatments ineffective.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Govt Siddha doctors in Kerala form new association to promote Siddha dispensaries in rural areas
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 25, 2022
The Siddha medical practitioners working under the Kerala ISM department and assigned with various Central and state government projects have joined hands to form an organisation of government Siddha medical officers on the lines of the Kerala Government Ayurveda Medical Officers Association. The new organisation of Siddha medical officers will be known as ‘Kerala Government […].
QiC Diabetes awards 2022 celebrate UK healthcare excellence
Pharma Times
OCTOBER 26, 2022
The annual awards recognise the efforts of NHS teams and individuals
Myovant agrees to sell after buyer ups price
Bio Pharma Dive
OCTOBER 24, 2022
Sumitomo Pharma, a Japanese drug company that already owns 52% of Myovant, is now offering to buy all the remaining shares for $27 apiece in a deal that values the biotech at $2.9 billion.
BMS reports 3% decline in total revenues in Q3 2022
Pharmaceutical Technology
OCTOBER 26, 2022
Bristol Myers Squibb (BMS) has reported a 3% decline in total revenues to $11.2bn in the third quarter (Q2) of 2022 as against $11.6bn in the year-ago quarter. The decline in Q3 revenue was driven by the latest LOE products, chiefly Revlimid, and impacts from foreign exchange. In-line products, namely Eliquis and Opdivo, as well as the latest product portfolio including Opdualag, Abecma and Reblozyl partially offset the decline in revenues.
Pharma exports report 6.86% growth in September
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 26, 2022
Pharmaceutical export during the month of September has registered a 6.86 per cent growth as compared to the same month of previous year. The first six months of the fiscal year has also registered a growth of 6.04 per cent compared to the same period of previous year, with a significant improvement from the growth […].
UK’s largest health research programme launched
Pharma Times
OCTOBER 25, 2022
Millions will be invited to join the programme to ‘prevent, detect and treat’ diseases
For Biogen investors, company’s outlook rests on next Alzheimer’s drug
Bio Pharma Dive
OCTOBER 25, 2022
The company’s latest earnings presentation saw analysts press for more details about the Alzheimer’s drug it’s developing with Eisai — and how the partners plan to avoid some of the pitfalls experienced with Aduhelm.
With hospitalizations ticking up, flu season appears off to an early start
STAT News
OCTOBER 28, 2022
There are increasing signs that flu season is off to a very early start in parts of the United States, with the cumulative hospitalization rate higher than it has been at this point in the fall for more than a decade, the Centers for Disease Control and Prevention reported Friday. In its weekly FluView report , the CDC estimated that there have already been 880,000 influenza illnesses, 6,900 flu hospitalizations, and 360 deaths caused by flu this season, which started at the beginning of October
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content